{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T21:04:24Z","timestamp":1785791064070,"version":"3.56.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003359","name":"Generalitat Valenciana","doi-asserted-by":"publisher","award":["FDEGENT\/2020\/001"],"award-info":[{"award-number":["FDEGENT\/2020\/001"]}],"id":[{"id":"10.13039\/501100003359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003359","name":"Generalitat Valenciana","doi-asserted-by":"publisher","award":["PROMETEO\/2020\/081"],"award-info":[{"award-number":["PROMETEO\/2020\/081"]}],"id":[{"id":"10.13039\/501100003359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"EC | European Regional Development Fund","doi-asserted-by":"publisher","award":["OP ERDF of Comunitat Valenciana 2014-2020"],"award-info":[{"award-number":["OP ERDF of Comunitat Valenciana 2014-2020"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010434","name":"\u2018la Caixa\u2019 Foundation","doi-asserted-by":"publisher","award":["HR17-00268"],"award-info":[{"award-number":["HR17-00268"]}],"id":[{"id":"10.13039\/100010434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["DTS19\/00128"],"award-info":[{"award-number":["DTS19\/00128"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lab Anim"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>HSA<jats:sup>LR<\/jats:sup> mice are the most broadly used animal model for studying myotonic dystrophy type I (DM1). However, so far, HSA<jats:sup>LR<\/jats:sup> preclinical studies have often excluded female mice or failed to document the biological sex of the animals. This leaves an unwanted knowledge gap concerning the differential development of DM1 in males and females, particularly considering that the disease has a different clinical presentation in men and women. Here we compared typical functional measurements, histological features, molecular phenotypes and biochemical plasma profiles in the muscles of male and female HSA<jats:sup>LR<\/jats:sup> mice in search of any significant between-sex differences that could justify this exclusion of female mice in HSA<jats:sup>LR<\/jats:sup> studies and, critically, in candidate therapy assays performed with this model. We found no fundamental differences between HSA<jats:sup>LR<\/jats:sup> males and females during disease development. Both sexes presented comparable functional and tissue phenotypes, with similar molecular muscle profiles. The only sex differences and significant interactions observed were in plasma biochemical parameters, which are also intrinsically variable in patients with DM1. In addition, we tested the influence of age on these measurements. We therefore suggest including female HSA<jats:sup>LR<\/jats:sup> mice in regular DM1 studies, and recommend documenting the sex of animals, especially in studies focusing on metabolic alterations. This will allow researchers to detect and report any potential differences between male and female HSA<jats:sup>LR<\/jats:sup> mice, especially regarding the efficacy of experimental treatments that could be relevant to patients with DM1.<\/jats:p>","DOI":"10.1038\/s41684-025-01506-7","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T12:38:32Z","timestamp":1740746312000},"page":"92-102","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Use of HSALR female mice as a model for the study of myotonic dystrophy type I"],"prefix":"10.1038","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5477-8323","authenticated-orcid":false,"given":"Marc","family":"Carrascosa-S\u00e0ez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2902-8237","authenticated-orcid":false,"given":"Anna","family":"Colom-Rodrigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Gonz\u00e1lez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"P\u00e9rez-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Garc\u00eda-Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Piqueras-Losilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Ballestar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Llamus\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3247-5900","authenticated-orcid":false,"given":"Estefan\u00eda","family":"Cerro-Herreros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1596-047X","authenticated-orcid":false,"given":"Ruben","family":"Artero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"1506_CR1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1159\/000524734","volume":"56","author":"Q Liao","year":"2022","unstructured":"Liao, Q., Zhang, Y., He, J. & Huang, K. Global prevalence of myotonic dystrophy: an updated systematic review and meta-analysis. Neuroepidemiology 56, 163\u2013173 (2022).","journal-title":"Neuroepidemiology"},{"key":"1506_CR2","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/0092-8674(92)90154-5","volume":"68","author":"JD Brook","year":"1992","unstructured":"Brook, J. D. et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3\u2032 end of a transcript encoding a protein kinase family member. Cell 68, 799\u2013808 (1992).","journal-title":"Cell"},{"key":"1506_CR3","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1126\/science.1546325","volume":"255","author":"M Mahadevan","year":"1992","unstructured":"Mahadevan, M. et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3\u2032 untranslated region of the gene. Science 255, 1253\u20131255 (1992).","journal-title":"Science"},{"key":"1506_CR4","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.ncl.2014.04.011","volume":"32","author":"CA Thornton","year":"2014","unstructured":"Thornton, C. A. Myotonic dystrophy. Neurol. Clin. 32, 705\u2013719 (2014).","journal-title":"Neurol. Clin."},{"key":"1506_CR5","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s13311-018-00679-z","volume":"15","author":"S LoRusso","year":"2018","unstructured":"LoRusso, S., Weiner, B. & Arnold, W. D. Myotonic dystrophies: targeting therapies for multisystem disease. Neurotherapeutics 15, 872\u2013884 (2018).","journal-title":"Neurotherapeutics"},{"key":"1506_CR6","doi-asserted-by":"publisher","unstructured":"Thomas, J. D., Oliveira, R., Sznajder, \u0141. J. & Swanson, M. S. Myotonic dystrophy and developmental regulation of RNA processing. Compr. Physiol. https:\/\/doi.org\/10.1002\/cphy.c170002 (2018).","DOI":"10.1002\/cphy.c170002"},{"key":"1506_CR7","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.1093\/emboj\/19.17.4439","volume":"19","author":"JW Miller","year":"2000","unstructured":"Miller, J. W. et al. Recruitment of human muscleblind proteins to (CUG)n expansions associated with myotonic dystrophy. EMBO J. 19, 4439\u20134448 (2000).","journal-title":"EMBO J."},{"key":"1506_CR8","doi-asserted-by":"publisher","first-page":"7388","DOI":"10.1073\/pnas.94.14.7388","volume":"94","author":"BM Davis","year":"1997","unstructured":"Davis, B. M., McCurrach, M. E., Taneja, K. L., Singer, R. H. & Housman, D. E. Expansion of a CUG trinucleotide repeat in the 3\u2032 untranslated region of myotonic dystrophy protein kinase transcripts results in nuclear retention of transcripts. Proc. Natl Acad. Sci. USA 94, 7388\u20137393 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1506_CR9","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1083\/jcb.128.6.995","volume":"128","author":"KL Taneja","year":"1995","unstructured":"Taneja, K. L., McCurrach, M., Schalling, M., Housman, D. & Singer, R. H. Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues. J. Cell Biol. 128, 995\u20131002 (1995).","journal-title":"J. Cell Biol."},{"key":"1506_CR10","first-page":"184","volume":"6","author":"B Llamusi","year":"2013","unstructured":"Llamusi, B. et al. Muscleblind, BSF and TBPH are mislocalized in the muscle sarcomere of a Drosophila myotonic dystrophy model. Dis. Model Mech. 6, 184\u2013196 (2013).","journal-title":"Dis. Model Mech."},{"key":"1506_CR11","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1126\/science.289.5485.1769","volume":"289","author":"A Mankodi","year":"2000","unstructured":"Mankodi, A. et al. Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science 289, 1769\u20131772 (2000).","journal-title":"Science"},{"key":"1506_CR12","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1126\/science.1088583","volume":"302","author":"RN Kanadia","year":"2003","unstructured":"Kanadia, R. N. et al. A muscleblind knockout model for myotonic dystrophy. Science 302, 1978\u20131980 (2003).","journal-title":"Science"},{"key":"1506_CR13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11940-016-0434-1","volume":"18","author":"CA Smith","year":"2016","unstructured":"Smith, C. A. & Gutmann, L. Myotonic dystrophy type 1 management and therapeutics. Curr. Treat. Options Neurol. 18, 52 (2016).","journal-title":"Curr. Treat. Options Neurol."},{"key":"1506_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3389\/fnagi.2015.00125","volume":"7","author":"AJ Mateos-Aierdi","year":"2015","unstructured":"Mateos-Aierdi, A. J. et al. Muscle wasting in myotonic dystrophies: a model of premature aging. Front. Aging Neurosci. 7, 125 (2015).","journal-title":"Front. Aging Neurosci."},{"key":"1506_CR15","doi-asserted-by":"publisher","first-page":"e0148264","DOI":"10.1371\/journal.pone.0148264","volume":"11","author":"C Dogan","year":"2016","unstructured":"Dogan, C. et al. Gender as a modifying factor influencing myotonic dystrophy type 1 phenotype severity and mortality: a nationwide multiple databases cross-sectional observational study. PLoS ONE 11, e0148264 (2016).","journal-title":"PLoS ONE"},{"key":"1506_CR16","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1038\/sj.emboj.7600300","volume":"23","author":"TH Ho","year":"2004","unstructured":"Ho, T. H. et al. Muscleblind proteins regulate alternative splicing. EMBO J. 23, 3103\u20133112 (2004).","journal-title":"EMBO J."},{"key":"1506_CR17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1432-0436.2006.00060.x","volume":"74","author":"M Pascual","year":"2006","unstructured":"Pascual, M., Vicente, M., Monferrer, L. & Artero, R. The Muscleblind family of proteins: an emerging class of regulators of developmentally programmed alternative splicing. Differentiation 74, 65\u201380 (2006).","journal-title":"Differentiation"},{"key":"1506_CR18","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1093\/hmg\/dds478","volume":"22","author":"JM Fernandez-Costa","year":"2013","unstructured":"Fernandez-Costa, J. M. et al. Expanded CTG repeats trigger miRNA alterations in Drosophila that are conserved in myotonic dystrophy type 1 patients. Hum. Mol. Genet. 22, 704\u2013716 (2013).","journal-title":"Hum. Mol. Genet."},{"key":"1506_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.nmd.2004.09.012","volume":"15","author":"JW Day","year":"2005","unstructured":"Day, J. W. & Ranum, L. P. W. RNA pathogenesis of the myotonic dystrophies. Neuromuscul. Disord. 15, 5\u201316 (2005).","journal-title":"Neuromuscul. Disord."},{"key":"1506_CR20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/ana.21948","volume":"67","author":"PK Todd","year":"2010","unstructured":"Todd, P. K. & Paulson, H. L. RNA-mediated neurodegeneration in repeat expansion disorders. Ann. Neurol. 67, 291\u2013300 (2010).","journal-title":"Ann. Neurol."},{"key":"1506_CR21","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1093\/hmg\/ddl132","volume":"15","author":"X Lin","year":"2006","unstructured":"Lin, X. et al. Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum. Mol. Genet. 15, 2087\u20132097 (2006).","journal-title":"Hum. Mol. Genet."},{"key":"1506_CR22","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.omtn.2021.07.017","volume":"26","author":"E Cerro-Herreros","year":"2021","unstructured":"Cerro-Herreros, E. et al. Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy. Mol Ther. Nucleic Acids 26, 174\u2013191 (2021).","journal-title":"Mol Ther. Nucleic Acids"},{"key":"1506_CR23","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.omtn.2019.11.012","volume":"19","author":"M Sabater-Arcis","year":"2020","unstructured":"Sabater-Arcis, M., Bargiela, A., Furling, D. & Artero, R. miR-7 restores phenotypes in myotonic dystrophy muscle cells by repressing hyperactivated autophagy. Mol. Ther. Nucleic Acids 19, 278\u2013292 (2020).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1506_CR24","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3389\/fneur.2020.00394","volume":"11","author":"A Perna","year":"2020","unstructured":"Perna, A. et al. High prevalence and gender-related differences of gastrointestinal manifestations in a cohort of DM1 patients: a perspective, cross-sectional study. Front. Neurol. 11, 394 (2020).","journal-title":"Front. Neurol."},{"key":"1506_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-021-02124-9","volume":"21","author":"G Solbakken","year":"2021","unstructured":"Solbakken, G. et al. Pain in adult myotonic dystrophy type 1: relation to function and gender. BMC Neurol. 21, 101 (2021).","journal-title":"BMC Neurol."},{"key":"1506_CR26","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3389\/fphys.2013.00363","volume":"4","author":"ES Folker","year":"2013","unstructured":"Folker, E. S. & Baylies, M. K. Nuclear positioning in muscle development and disease. Front. Physiol. 4, 363 (2013).","journal-title":"Front. Physiol."},{"key":"1506_CR27","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.ydbio.2003.07.021","volume":"265","author":"JD Amack","year":"2004","unstructured":"Amack, J. D. & Mahadevan, M. S. Myogenic defects in myotonic dystrophy. Dev. Biol. 265, 294\u2013301 (2004).","journal-title":"Dev. Biol."},{"key":"1506_CR28","doi-asserted-by":"publisher","first-page":"11748","DOI":"10.1073\/pnas.0604970103","volume":"103","author":"RN Kanadia","year":"2006","unstructured":"Kanadia, R. N. et al. Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. Proc. Natl Acad. Sci. USA 103, 11748\u201311753 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1506_CR29","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/mus.20809","volume":"36","author":"M Nakamori","year":"2007","unstructured":"Nakamori, M., Kimura, T., Fujimura, H., Takahashi, M. P. & Sakoda, S. Altered mRNA splicing of dystrophin in type 1 myotonic dystrophy. Muscle Nerve 36, 251\u2013257 (2007).","journal-title":"Muscle Nerve"},{"key":"1506_CR30","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1093\/hmg\/ddi223","volume":"14","author":"T Kimura","year":"2005","unstructured":"Kimura, T. et al. Altered mRNA splicing of the skeletal muscle ryanodine receptor and sarcoplasmic\/endoplasmic reticulum Ca2+-ATPase in myotonic dystrophy type 1. Hum. Mol. Genet. 14, 2189\u20132200 (2005).","journal-title":"Hum. Mol. Genet."},{"key":"1506_CR31","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1126\/science.327.5973.1571","volume":"327","author":"C Wald","year":"2010","unstructured":"Wald, C. & Wu, C. Of mice and women: the bias in animal models. Science 327, 1571\u20131572 (2010).","journal-title":"Science"},{"key":"1506_CR32","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/464332b","volume":"464","author":"E Check Hayden","year":"2010","unstructured":"Check Hayden, E. Sex bias blights drug studies. Nature 464, 332\u2013333 (2010).","journal-title":"Nature"},{"key":"1506_CR33","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1126\/science.aaw7570","volume":"364","author":"RM Shansky","year":"2019","unstructured":"Shansky, R. M. Are hormones a \u2018female problem\u2019 for animal research? Science 364, 825\u2013826 (2019).","journal-title":"Science"},{"key":"1506_CR34","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1038\/550S18a","volume":"550","author":"A Nowogrodzki","year":"2017","unstructured":"Nowogrodzki, A. Inequality in medicine. Nature 550, S18\u2013S19 (2017).","journal-title":"Nature"},{"key":"1506_CR35","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1177\/0023677213498717","volume":"48","author":"NH Franco","year":"2014","unstructured":"Franco, N. H. & Olsson, Ia. S. Scientists and the 3Rs: attitudes to animal use in biomedical research and the effect of mandatory training in laboratory animal science. Lab Anim. 48, 50\u201360 (2014).","journal-title":"Lab Anim."},{"key":"1506_CR36","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1111\/ene.14665","volume":"28","author":"M Garibaldi","year":"2021","unstructured":"Garibaldi, M. et al. Gender effect on cardiac involvement in myotonic dystrophy type 1. Eur. J. Neurol. 28, 1366\u20131374 (2021).","journal-title":"Eur. J. Neurol."},{"key":"1506_CR37","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.nmd.2017.04.007","volume":"27","author":"K Raymond","year":"2017","unstructured":"Raymond, K., Levasseur, M., Mathieu, J., Desrosiers, J. & Gagnon, C. A 9-year follow-up study of the natural progression of upper limb performance in myotonic dystrophy type 1: a similar decline for phenotypes but not for gender. Neuromuscul. Disord. 27, 673\u2013682 (2017).","journal-title":"Neuromuscul. Disord."},{"key":"1506_CR38","doi-asserted-by":"publisher","first-page":"4971","DOI":"10.1093\/hmg\/ddv219","volume":"24","author":"DR Bisset","year":"2015","unstructured":"Bisset, D. R. et al. Therapeutic impact of systemic AAV-mediated RNA interference in a mouse model of myotonic dystrophy. Hum. Mol. Genet. 24, 4971\u20134983 (2015).","journal-title":"Hum. Mol. Genet."},{"key":"1506_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2024.102338","volume":"35","author":"SM Hicks","year":"2024","unstructured":"Hicks, S. M. et al. Alternative splicing dysregulation across tissue and therapeutic approaches in a mouse model of myotonic dystrophy type 1. Mol. Ther. Nucleic Acids 35, 102338 (2024).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1506_CR40","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1126\/science.1173110","volume":"325","author":"TM Wheeler","year":"2009","unstructured":"Wheeler, T. M. et al. Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science 325, 336\u2013339 (2009).","journal-title":"Science"},{"key":"1506_CR41","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/WCO.0000000000000128","volume":"27","author":"C Turner","year":"2014","unstructured":"Turner, C. & Hilton-Jones, D. Myotonic dystrophy: diagnosis, management and new therapies. Curr. Opin. Neurol. 27, 599\u2013606 (2014).","journal-title":"Curr. Opin. Neurol."},{"key":"1506_CR42","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/mus.26709","volume":"60","author":"L Sharp","year":"2019","unstructured":"Sharp, L., Cox, D. C. & Cooper, T. A. Endurance exercise leads to beneficial molecular and physiological effects in a mouse model of myotonic dystrophy type 1. Muscle Nerve 60, 779\u2013789 (2019).","journal-title":"Muscle Nerve"},{"key":"1506_CR43","doi-asserted-by":"publisher","first-page":"4461","DOI":"10.1172\/JCI64081","volume":"122","author":"K Jones","year":"2012","unstructured":"Jones, K. et al. GSK3\u03b2 mediates muscle pathology in myotonic dystrophy. J. Clin. Invest. 122, 4461\u20134472 (2012).","journal-title":"J. Clin. Invest."},{"key":"1506_CR44","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1096\/fj.201700700R","volume":"32","author":"C Wei","year":"2018","unstructured":"Wei, C. et al. Correction of GSK3\u03b2 at young age prevents muscle pathology in mice with myotonic dystrophy type 1. FASEB J. 32, 2073\u20132085 (2018).","journal-title":"FASEB J."},{"key":"1506_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/srep25317","volume":"6","author":"G Chen","year":"2016","unstructured":"Chen, G. et al. Phenylbutazone induces expression of MBNL1 and suppresses formation of MBNL1-CUG RNA foci in a mouse model of myotonic dystrophy. Sci Rep. 6, 25317 (2016).","journal-title":"Sci Rep."},{"key":"1506_CR46","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00155-19","volume":"39","author":"M Wang","year":"2019","unstructured":"Wang, M. et al. Correction of glycogen synthase kinase 3\u03b2 in myotonic dystrophy 1 reduces the mutant RNA and improves postnatal survival of DMSXL mice. Mol. Cell. Biol. 39, e00155-19 (2019).","journal-title":"Mol. Cell. Biol."},{"key":"1506_CR47","doi-asserted-by":"publisher","first-page":"e26555","DOI":"10.4161\/rdis.26555","volume":"1","author":"C Wei","year":"2013","unstructured":"Wei, C., Jones, K., Timchenko, N. A. & Timchenko, L. GSK3\u03b2 is a new therapeutic target for myotonic dystrophy type 1. Rare Dis. 1, e26555 (2013).","journal-title":"Rare Dis."},{"key":"1506_CR48","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1093\/hmg\/ddn301","volume":"17","author":"GB Banks","year":"2008","unstructured":"Banks, G. B., Combs, A. C., Chamberlain, J. R. & Chamberlain, J. S. Molecular and cellular adaptations to chronic myotendinous strain injury in mdx mice expressing a truncated dystrophin. Hum. Mol. Genet. 17, 3975\u20133986 (2008).","journal-title":"Hum. Mol. Genet."},{"key":"1506_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-27661-w","volume":"13","author":"A Bargiela","year":"2023","unstructured":"Bargiela, A. et al. Quantitative magnetic resonance imaging assessment of muscle composition in myotonic dystrophy mice. Sci. Rep. 13, 503 (2023).","journal-title":"Sci. Rep."},{"key":"1506_CR50","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.omtn.2022.02.003","volume":"27","author":"SJ Overby","year":"2022","unstructured":"Overby, S. J. et al. Proof of concept of peptide-linked blockmiR-induced MBNL functional rescue in myotonic dystrophy type 1 mouse model. Mol. Ther. Nucleic Acids 27, 1146\u20131155 (2022).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1506_CR51","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1093\/nar\/29.13.2766","volume":"29","author":"M Fardaei","year":"2001","unstructured":"Fardaei, M., Larkin, K., Brook, J. D. & Hamshere, M. G. In vivo co-localisation of MBNL protein with DMPK expanded-repeat transcripts. Nucleic Acids Res. 29, 2766\u20132771 (2001).","journal-title":"Nucleic Acids Res."},{"key":"1506_CR52","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1093\/hmg\/ddh327","volume":"13","author":"H Jiang","year":"2004","unstructured":"Jiang, H., Mankodi, A., Swanson, M. S., Moxley, R. T. & Thornton, C. A. Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. Hum. Mol. Genet. 13, 3079\u20133088 (2004).","journal-title":"Hum. Mol. Genet."},{"key":"1506_CR53","doi-asserted-by":"publisher","first-page":"216","DOI":"10.2353\/ajpath.2009.080520","volume":"174","author":"I Holt","year":"2009","unstructured":"Holt, I. et al. Muscleblind-like proteins: similarities and differences in normal and myotonic dystrophy muscle. Am. J. Pathol. 174, 216\u2013227 (2009).","journal-title":"Am. J. Pathol."},{"key":"1506_CR54","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1002\/emmm.201303275","volume":"5","author":"K-Y Lee","year":"2013","unstructured":"Lee, K.-Y. et al. Compound loss of muscleblind-like function in myotonic dystrophy. EMBO Mol. Med. 5, 1887\u20131900 (2013).","journal-title":"EMBO Mol. Med."},{"key":"1506_CR55","doi-asserted-by":"publisher","first-page":"25203","DOI":"10.1073\/pnas.1820297116","volume":"116","author":"A Bargiela","year":"2019","unstructured":"Bargiela, A. et al. Increased Muscleblind levels by chloroquine treatment improve myotonic dystrophy type 1 phenotypes in in vitro and in vivo models. Proc. Natl Acad. Sci. USA 116, 25203\u201325213 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1506_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04892-4","volume":"9","author":"E Cerro-Herreros","year":"2018","unstructured":"Cerro-Herreros, E. et al. miR-23b and miR-218 silencing increase Muscleblind-like expression and alleviate myotonic dystrophy phenotypes in mammalian models. Nat. Commun. 9, 2482 (2018).","journal-title":"Nat. Commun."},{"key":"1506_CR57","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.3390\/genes11091109","volume":"11","author":"A L\u00f3pez-Mart\u00ednez","year":"2020","unstructured":"L\u00f3pez-Mart\u00ednez, A., Soblechero-Mart\u00edn, P., de-la-Puente-Ovejero, L., Nogales-Gadea, G. & Arechavala-Gomeza, V. An overview of alternative splicing defects implicated in myotonic dystrophy type I. Genes 11, 1109 (2020).","journal-title":"Genes"},{"key":"1506_CR58","doi-asserted-by":"publisher","first-page":"e33218","DOI":"10.1371\/journal.pone.0033218","volume":"7","author":"K Suenaga","year":"2012","unstructured":"Suenaga, K. et al. Muscleblind-like 1 knockout mice reveal novel splicing defects in the myotonic dystrophy brain. PLoS ONE 7, e33218 (2012).","journal-title":"PLoS ONE"},{"key":"1506_CR59","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nsmb.1720","volume":"17","author":"H Du","year":"2010","unstructured":"Du, H. et al. Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophy. Nat. Struct. Mol. Biol. 17, 187\u2013193 (2010).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1506_CR60","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.molcel.2014.08.027","volume":"56","author":"R Batra","year":"2014","unstructured":"Batra, R. et al. Loss of MBNL leads to disruption of developmentally regulated alternative polyadenylation in RNA-mediated disease. Mol. Cell 56, 311\u2013322 (2014).","journal-title":"Mol. Cell"},{"key":"1506_CR61","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1002\/ana.23992","volume":"74","author":"M Nakamori","year":"2013","unstructured":"Nakamori, M. et al. Splicing biomarkers of disease severity in myotonic dystrophy. Ann. Neurol. 74, 862\u2013872 (2013).","journal-title":"Ann. Neurol."},{"key":"1506_CR62","doi-asserted-by":"publisher","first-page":"5472","DOI":"10.1073\/pnas.1907297117","volume":"117","author":"M Li","year":"2020","unstructured":"Li, M. et al. HNRNPA1-induced spliceopathy in a transgenic mouse model of myotonic dystrophy. Proc. Natl Acad. Sci. USA 117, 5472\u20135477 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1506_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37619-1","volume":"14","author":"N Hu","year":"2023","unstructured":"Hu, N., Kim, E., Antoury, L. & Wheeler, T. M. Correction of Clcn1 alternative splicing reverses muscle fiber type transition in mice with myotonic dystrophy. Nat. Commun. 14, 1956 (2023).","journal-title":"Nat. Commun."},{"key":"1506_CR64","doi-asserted-by":"publisher","first-page":"e1006316","DOI":"10.1371\/journal.pgen.1006316","volume":"12","author":"SD Wagner","year":"2016","unstructured":"Wagner, S. D. et al. Dose-dependent regulation of alternative splicing by MBNL proteins reveals biomarkers for myotonic dystrophy. PLoS Genet. 12, e1006316 (2016).","journal-title":"PLoS Genet."},{"key":"1506_CR65","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/jhg.2012.37","volume":"57","author":"Y Yamashita","year":"2012","unstructured":"Yamashita, Y. et al. Four parameters increase the sensitivity and specificity of the exon array analysis and disclose 25 novel aberrantly spliced exons in myotonic dystrophy. J. Hum. Genet. 57, 368\u2013374 (2012).","journal-title":"J. Hum. Genet."},{"key":"1506_CR66","doi-asserted-by":"crossref","unstructured":"Mondragon-Gonzalez, R., Azzag, K., Selvaraj, S., Yamamoto, A. & Perlingeiro, R. C. R. Transplantation studies reveal internuclear transfer of toxic RNA in engrafted muscles of myotonic dystrophy 1 mice. eBioMedicine 47, 553\u2013562 (2019).","DOI":"10.1016\/j.ebiom.2019.08.031"},{"key":"1506_CR67","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1085\/jgp.200609635","volume":"129","author":"JD Lueck","year":"2007","unstructured":"Lueck, J. D., Mankodi, A., Swanson, M. S., Thornton, C. A. & Dirksen, R. T. Muscle chloride channel dysfunction in two mouse models of myotonic dystrophy. J. Gen. Physiol. 129, 79\u201394 (2007).","journal-title":"J. Gen. Physiol."},{"key":"1506_CR68","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S1097-2765(02)00572-5","volume":"10","author":"N Charlet-B","year":"2002","unstructured":"Charlet-B, N. et al. Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Mol. Cell 10, 45\u201353 (2002).","journal-title":"Mol. Cell"},{"key":"1506_CR69","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1097-2765(02)00563-4","volume":"10","author":"A Mankodi","year":"2002","unstructured":"Mankodi, A. et al. Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol. Cell 10, 35\u201344 (2002).","journal-title":"Mol. Cell"},{"key":"1506_CR70","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nm.2374","volume":"17","author":"C Fugier","year":"2011","unstructured":"Fugier, C. et al. Misregulated alternative splicing of BIN1 is associated with T tubule alterations and muscle weakness in myotonic dystrophy. Nat. Med. 17, 720\u2013725 (2011).","journal-title":"Nat. Med."},{"key":"1506_CR71","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/hmg\/ddr568","volume":"21","author":"ZZ Tang","year":"2012","unstructured":"Tang, Z. Z. et al. Muscle weakness in myotonic dystrophy associated with misregulated splicing and altered gating of CaV1.1 calcium channel. Hum. Mol. Genet. 21, 1312\u20131324 (2012).","journal-title":"Hum. Mol. Genet."},{"key":"1506_CR72","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.omtn.2020.11.014","volume":"23","author":"N Hu","year":"2021","unstructured":"Hu, N. et al. Antisense oligonucleotide and adjuvant exercise therapy reverse fatigue in old mice with myotonic dystrophy. Mol. Ther. Nucleic Acids 23, 393\u2013405 (2021).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1506_CR73","unstructured":"Farhana, A. & Lappin, S. L. Biochemistry, Lactate Dehydrogenase (StatPearls, 2023)."},{"key":"1506_CR74","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/ajcn\/80.2.357","volume":"80","author":"G Perseghin","year":"2004","unstructured":"Perseghin, G. et al. Postabsorptive and insulin-stimulated energy and protein metabolism in patients with myotonic dystrophy type 1. Am. J. Clin. Nutr. 80, 357\u2013364 (2004).","journal-title":"Am. J. Clin. Nutr."},{"key":"1506_CR75","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.apmr.2004.09.012","volume":"86","author":"S Aitkens","year":"2005","unstructured":"Aitkens, S., Kilmer, D. D., Wright, N. C. & McCrory, M. A. Metabolic syndrome in neuromuscular disease. Arch. Phys. Med. Rehabil. 86, 1030\u20131036 (2005).","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"1506_CR76","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/mus.24540","volume":"52","author":"M Vujnic","year":"2015","unstructured":"Vujnic, M. et al. Metabolic syndrome in patients with myotonic dystrophy type 1. Muscle Nerve 52, 273\u2013277 (2015).","journal-title":"Muscle Nerve"},{"key":"1506_CR77","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1600-0404.2009.01237.x","volume":"121","author":"V Rakocevic Stojanovic","year":"2010","unstructured":"Rakocevic Stojanovic, V. et al. Leptin and the metabolic syndrome in patients with myotonic dystrophy type 1. Acta Neurol. Scand. 121, 94\u201398 (2010).","journal-title":"Acta Neurol. Scand."},{"key":"1506_CR78","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/mus.21484","volume":"41","author":"K Shieh","year":"2010","unstructured":"Shieh, K., Gilchrist, J. M. & Promrat, K. Frequency and predictors of nonalcoholic fatty liver disease in myotonic dystrophy. Muscle Nerve 41, 197\u2013201 (2010).","journal-title":"Muscle Nerve"},{"key":"1506_CR79","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s40618-019-01156-w","volume":"43","author":"M Spaziani","year":"2020","unstructured":"Spaziani, M. et al. Hormonal and metabolic gender differences in a cohort of myotonic dystrophy type 1 subjects: a retrospective, case-control study. J. Endocrinol. Invest. 43, 663\u2013675 (2020).","journal-title":"J. Endocrinol. Invest."},{"key":"1506_CR80","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1172\/JCI109198","volume":"62","author":"RT Moxley","year":"1978","unstructured":"Moxley, R. T. et al. Decreased insulin sensitivity of forearm muscle in myotonic dystrophy. J. Clin. Invest. 62, 857\u2013867 (1978).","journal-title":"J. Clin. Invest."},{"key":"1506_CR81","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1001\/archneur.63.8.1149","volume":"63","author":"CR Heatwole","year":"2006","unstructured":"Heatwole, C. R., Miller, J., Martens, B. & Moxley, R. T. Laboratory abnormalities in ambulatory patients with myotonic dystrophy type 1. Arch. Neurol. 63, 1149\u20131153 (2006).","journal-title":"Arch. Neurol."},{"key":"1506_CR82","doi-asserted-by":"publisher","first-page":"e2803","DOI":"10.1212\/WNL.0000000000007648","volume":"92","author":"L Heskamp","year":"2019","unstructured":"Heskamp, L. et al. Lower extremity muscle pathology in myotonic dystrophy type 1 assessed by quantitative MRI. Neurology 92, e2803\u2013e2814 (2019).","journal-title":"Neurology"},{"key":"1506_CR83","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1757-1626-2-7","volume":"2","author":"M Gagliano","year":"2009","unstructured":"Gagliano, M. et al. Low-intensity body building exercise induced rhabdomyolysis: a case report. Cases J. 2, 7 (2009).","journal-title":"Cases J."},{"key":"1506_CR84","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/00004836-199806000-00016","volume":"26","author":"A Achiron","year":"1998","unstructured":"Achiron, A. et al. Abnormal liver test results in myotonic dystrophy. J. Clin. Gastroenterol. 26, 292\u2013295 (1998).","journal-title":"J. Clin. Gastroenterol."},{"key":"1506_CR85","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.cmet.2014.12.021","volume":"21","author":"KK Baskin","year":"2015","unstructured":"Baskin, K. K., Winders, B. R. & Olson, E. N. Muscle as a \u2018mediator\u2019 of systemic metabolism. Cell Metab 21, 237\u2013248 (2015).","journal-title":"Cell Metab"},{"key":"1506_CR86","doi-asserted-by":"crossref","unstructured":"Argil\u00e9s, J. M., Campos, N., Lopez-Pedrosa, J. M., Rueda, R. & Rodriguez-Ma\u00f1as, L. Skeletal muscle regulates metabolism via interorgan crosstalk: roles in health and disease. J. Am. Med. Dir. Assoc. 17, 789\u2013796 (2016).","DOI":"10.1016\/j.jamda.2016.04.019"},{"key":"1506_CR87","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1083\/jcb.201108113","volume":"196","author":"A Ravel-Chapuis","year":"2012","unstructured":"Ravel-Chapuis, A. et al. The RNA-binding protein Staufen1 is increased in DM1 skeletal muscle and promotes alternative pre-mRNA splicing. J. Cell Biol. 196, 699\u2013712 (2012).","journal-title":"J. Cell Biol."},{"key":"1506_CR88","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.phrs.2008.07.011","volume":"58","author":"I Klinge","year":"2008","unstructured":"Klinge, I. Gender perspectives in European research. Pharmacol. Res. 58, 183\u2013189 (2008).","journal-title":"Pharmacol. Res."},{"key":"1506_CR89","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12939-019-0954-x","volume":"18","author":"A Yakerson","year":"2019","unstructured":"Yakerson, A. Women in clinical trials: a review of policy development and health equity in the Canadian context. Int. J. Equity Health 18, 56 (2019).","journal-title":"Int. J. Equity Health"},{"key":"1506_CR90","doi-asserted-by":"publisher","unstructured":"Jones-Bolin, S. Guidelines for the care and use of laboratory animals in biomedical research. Curr. Protoc. Pharmacol. https:\/\/doi.org\/10.1002\/0471141755.pha04bs59 (2012).","DOI":"10.1002\/0471141755.pha04bs59"},{"key":"1506_CR91","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1113\/jphysiol.2012.246546","volume":"591","author":"M DiFranco","year":"2013","unstructured":"DiFranco, M., Yu, C., Qui\u00f1onez, M. & Vergara, J. L. Age-dependent chloride channel expression in skeletal muscle fibres of normal and HSA(LR) myotonic mice. J. Physiol. 591, 1347\u20131371 (2013).","journal-title":"J. Physiol."},{"key":"1506_CR92","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1093\/hmg\/ddac222","volume":"32","author":"NS Misquitta","year":"2023","unstructured":"Misquitta, N. S., Ravel-Chapuis, A. & Jasmin, B. J. Combinatorial treatment with exercise and AICAR potentiates the rescue of myotonic dystrophy type 1 mouse muscles in a sex-specific manner. Hum. Mol. Genet. 32, 551\u2013566 (2023).","journal-title":"Hum. Mol. Genet."},{"key":"1506_CR93","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/978-1-0716-2010-6_13","volume":"2434","author":"N Moreno","year":"2022","unstructured":"Moreno, N., Gonz\u00e1lez-Mart\u00ednez, I., Artero, R. & Cerro-Herreros, E. Rapid determination of MBNL1 protein levels by quantitative dot blot for the evaluation of antisense oligonucleotides in myotonic dystrophy myoblasts. Methods Mol. Biol. 2434, 207\u2013215 (2022).","journal-title":"Methods Mol. Biol."}],"container-title":["Lab Animal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41684-025-01506-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41684-025-01506-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41684-025-01506-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T22:12:27Z","timestamp":1743459147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41684-025-01506-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":93,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1506"],"URL":"https:\/\/doi.org\/10.1038\/s41684-025-01506-7","relation":{},"ISSN":["0093-7355","1548-4475"],"issn-type":[{"value":"0093-7355","type":"print"},{"value":"1548-4475","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"28 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}